Press Releases Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
3.85 ^USD	+3.77%		-6.10%	-10.26%

Jun. 03	Vgxi Inc. Announces Strategic Partnership with Sutro Biopharma Inc. to Support Growing Clinical Pipeline	CI
May. 13	Sutro Biopharma Q1 Loss Widens, Revenue Rises	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones	May. 13	AQ
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial	Apr. 30	AQ
Sutro Biopharma : Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”	Apr. 04	PU
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	Apr. 02	AQ
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	Mar. 25	AQ
Sutro Biopharma to Participate in Upcoming Investor Conferences	Feb. 06	AQ
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC	Jan. 04	AQ
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR-targeted ADC, on January 4, 2024	Dec. 15	AQ
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024	Dec. 14	AQ
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed, Refractory CBF/GLIS Presented at ASH 2023	Dec. 12	AQ
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	Dec. 11	AQ
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit	Dec. 04	AQ
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates	Nov. 27	AQ
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer	Nov. 21	AQ
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones	Nov. 13	AQ
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023	23-10-23	AQ
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023	23-10-22	AQ
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference	23-10-16	AQ
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer	23-09-19	AQ
Sutro Biopharma to Participate in Upcoming Investor Conferences	23-08-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Press Releases

Filters